Skip to main content

Branded

  • The push for pharmacist provider status

    Pharmacists traditionally have been one of the most underutilized members of the healthcare team, possibly because they hadn’t been officially recognized as part of that team. That, however, is about to change.

  • Actavis to pare down sales staff of branded-drugs division

    DUBLIN — Actavis will lay off more than 30% of the sales staff from its branded-drugs division as part of its acquisition of Warner Chilcott, the drug maker said.

  • Enlisting patients in the drive to improve Rx

    Nowhere is the need to engage more effectively with patients  more apparent than in the area of medication adherence.

    “Over 50% of patients with chronic conditions stop taking their medications,” said Diane Gilworth, a geriatric nurse practitioner and chief clinical officer for Dovetail Health. “So we have to find a way to help patients take better care of themselves.”

  • Greatest phase-2, phase-3 drug R&D activity seen in oncology, report finds

    BURLINGTON, Mass. — While drug companies are developing treatments for a wide variety of diseases, the greatest amount of mid- to late-stage research and development activity is in cancer treatments, according to a new report.

    According to healthcare market research company Decision Resources, among the top 25 drug companies, oncology is the focus for 30% of phase-2 drugs and 22% of phase-3 drugs. Other areas seeing strong activity include drugs for obesity, diabetes, infections and central nervous system disorders.

  • Engaging patients: Health care’s new ‘holy grail’

    It has been called “the blockbuster drug of the century,” the holy grail of health care and the next great frontier in the search for a more responsive and cost-effective healthcare system. But is it a truly achievable goal, and will it really transform the way health care is delivered in the United States?

  • Oral drugs gain on injectables in multiple sclerosis market, study finds

    BURLINGTON, Mass. — Use of injectable drugs for multiple sclerosis declined during the 12-month period that ended on June 30 as orally administered drugs for the condition became more popular, according to a new report.

  • Spending on drugs in the United States expected to grow again next year after falling

    NEW YORK — Global spending on drugs will pass the $1 trillion mark next year, according to a new study by the IMS Institute for Healthcare Informatics, a division of healthcare market analysis firm IMS Health.

  • Upsher-Smith to present phase-3 trial data of experimental epilepsy drug

    MAPLE GROVE, Minn. – Drug maker Upsher-Smith Labs will present data from a late-stage trial of a drug for treating epilepsy, the company said Monday.

X
This ad will auto-close in 10 seconds